Treatment of prostate cancer with regional lymph node (N1) metastasis

Alan Pollack; Eric M. Horwitz; Ben Movsas

doi:10.1016/S1053-4296(03)70005-8

Treatment of prostate cancer with regional lymph node (N1) metastasis

Alan Pollack, Eric M. Horwitz, Ben Movsas

Fox Chase Cancer Center

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.

Original language	English
Pages (from-to)	121-129
Number of pages	9
Journal	Seminars in Radiation Oncology
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/S1053-4296(03)70005-8
State	Published - Apr 2003

Keywords

Androgen Antagonists/therapeutic use
Combined Modality Therapy
Humans
Incidence
Lymphatic Irradiation
Lymphatic Metastasis/radiotherapy
Male
Neoplasm Staging
Prognosis
Prostatectomy
Prostatic Neoplasms/diagnosis
Risk Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1053-4296(03)70005-8

Cite this

@article{063e28ab91d94d5c9c362a5c97f4696b,

title = "Treatment of prostate cancer with regional lymph node (N1) metastasis",

abstract = "Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.",

keywords = "Androgen Antagonists/therapeutic use, Combined Modality Therapy, Humans, Incidence, Lymphatic Irradiation, Lymphatic Metastasis/radiotherapy, Male, Neoplasm Staging, Prognosis, Prostatectomy, Prostatic Neoplasms/diagnosis, Risk Factors",

author = "Alan Pollack and Horwitz, {Eric M.} and Ben Movsas",

year = "2003",

month = apr,

doi = "10.1016/S1053-4296(03)70005-8",

language = "English",

volume = "13",

pages = "121--129",

journal = "Seminars in Radiation Oncology",

issn = "1053-4296",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of prostate cancer with regional lymph node (N1) metastasis

AU - Pollack, Alan

AU - Horwitz, Eric M.

AU - Movsas, Ben

PY - 2003/4

Y1 - 2003/4

N2 - Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.

AB - Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.

KW - Androgen Antagonists/therapeutic use

KW - Combined Modality Therapy

KW - Humans

KW - Incidence

KW - Lymphatic Irradiation

KW - Lymphatic Metastasis/radiotherapy

KW - Male

KW - Neoplasm Staging

KW - Prognosis

KW - Prostatectomy

KW - Prostatic Neoplasms/diagnosis

KW - Risk Factors

UR - http://www.scopus.com/inward/record.url?scp=0037629107&partnerID=8YFLogxK

U2 - 10.1016/S1053-4296(03)70005-8

DO - 10.1016/S1053-4296(03)70005-8

M3 - Review article

C2 - 12728441

AN - SCOPUS:0037629107

SN - 1053-4296

VL - 13

SP - 121

EP - 129

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

IS - 2

ER -

Treatment of prostate cancer with regional lymph node (N1) metastasis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this